Homologous Recombination Deficiency (HRD) testing helps personalize treatment for ovarian cancer by identifying tumors with impaired DNA repair mechanisms. Patients with HRD-positive tumors, including those with BRCA1/2 mutations, may benefit from targeted therapies like PARP inhibitors. This test enables oncologists to tailor treatment plans, improve outcomes, and avoid unnecessary side effects.
30 days upon receipt of sample in the lab.